ARAC status report: 1985

The Atmospheric Release Advisory Capability is a real-time emergency-response service available to federal and state agencies for providing estimates of the environmental consequences of accidental releases of radioactivity into the atmosphere. This includes the estimation of radiation doses to nearby population centers and the levels and extent of surface contamination. The service is currently being expanded to support the emergency response plans at approximately 50 Department of Defense and Department of Energy facilities. This expansion consists of the installation of enhanced computational and data communications and processing systems, development of terrain and geographic data bases, improvements in modeling capabilities, as well as increased staff housing facilities. This report summarizes the current status of ARAC and the requirements to receive the service

Utilization of the atmospheric release advisory capability (ARAC) services during and after the Three Mile Island accident

At 0820 PST on 28 March 1979, the Department of Energy's Emergency Operations Center advised the Atmospheric Release Advisory Capability (ARAC) that the Three Mile Island nuclear power plant in Harrisburg, Pennsylvania, had experienced an accident some four hours earlier, resulting in the atmospheric release of xenon-133 and krypton-88. This report describes ARAC's response to the Three Mile Island accident, including the role ARAC played throughout the 20 days that real-time assessments were made available to the Department of Energy on-scene commander. It also describes the follow-up population-dose calculations performed for the President's Commission on Three Mile Island. At the request of the Nuclear Regulatory Commission, a questionnaire addressing the usefulness of ARAC products during the accident was sent to ARAC-product users. A summary of the findings from this questionnaire, along with recommendations for improving ARAC service, is also presented. The accident at Mississauga, Ontario, Canada, is discussed in the context of a well-planned emergency response by local and Federal officials

LKB1 Is the upstream kinase in the AMP-activated protein kinase cascade

Inactivating mutations in the protein kinase LKB1 lead to a dominantly inherited cancer in humans termed Peutz-Jeghers syndrome 1, 2. The role of LKB1 is unclear, and only one target for LKB1 has been identified in vivo [3]. AMP-activated protein kinase (AMPK) is the downstream component of a protein kinase cascade that plays a pivotal role in energy homeostasis [4]. AMPK may have a role in protecting the body from metabolic diseases including type 2 diabetes 5, 6, obesity [7], and cardiac hypertrophy [8]. We previously reported the identification of three protein kinases (Elm1, Pak1, and Tos3 [9]) that lie upstream of Snf1, the yeast homologue of AMPK. LKB1 shares sequence similarity with Elm1, Pak1, and Tos3, and we demonstrated that LKB1 phosphorylates AMPK on the activation loop threonine (Thr172) within the catalytic subunit and activates AMPK in vitro [9]. Here, we have investigated whether LKB1 corresponds to the major AMPKK activity present in cell extracts. AMPKK purified from rat liver corresponds to LKB1, and blocking LKB1 activity in cells abolishes AMPK activation in response to different stimuli. These results identify a link between two protein kinases, previously thought to lie in unrelated, distinct pathways, that are associated with human diseases

Shining a light on posterior cortical atrophy

Posterior cortical atrophy (PCA) is a clinicoradiologic syndrome characterized by progressive decline in visual processing skills, relatively intact memory and language in the early stages, and atrophy of posterior brain regions. Misdiagnosis of PCA is common, owing not only to its relative rarity and unusual and variable presentation, but also because patients frequently first seek the opinion of an ophthalmologist, who may note normal eye examinations by their usual tests but may not appreciate cortical brain dysfunction. Seeking to raise awareness of the disease, stimulate research, and promote collaboration, a multidisciplinary group of PCA research clinicians formed an international working party, which had its first face-to-face meeting on July 13, 2012 in Vancouver, Canada, prior to the Alzheimer's Association International Conference. © 2013 The Alzheimer's Association. All rights reserved